Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses

Fig. 2

Verification of the immune subtypes in validation cohort 1. a Heatmap representation of the expression of immune-related signatures between A-IS, E-IS, and non-IS in validation cohort 1 (n = 150). In the heatmap, high and low ssGSEA scores are represented in red and blue, respectively. The presence and molecular characteristics of the immune subtypes were successfully validated. be Kaplan–Meier curves for progression-free survival (b), overall survival (c), distant failure-free survival (d), and locoregional failure-free survival (e) according to immune subtypes in validation cohort 1 (n = 150). Cox regression HRs and 95% CIs obtained after correcting for age (>45 vs. ≤45 years), sex (male vs. female), T (T3–4 vs. T1–2) and N (N3–4 vs. N0–1) categories, and plasma EBV DNA (>2,000 vs. ≤2,000 copies/mL) are shown along with the corresponding Cox regression P-values. A-IS, active immune subtype; CAF, cancer-associated fibroblast; EBV, Epstein–Barr virus; ECM, extracellular matrix; E-IS, evaded immune subtype; MDSC, myeloid-derived suppressor cell; non-IS, non-immune subtype; ssGSEA, single-sample gene set enrichment analysis; TAM, tumour-associated macrophage

Back to article page